The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The potential role of the gut microbiome in MPNs
Christina Dalbøge, PhD, University Hospital of Region Zealand, Slagelse, Denmark, discusses the potential role of the gut microbiome in myeloproliferative neoplasm (MPN) biology, highlighting that patients with MPNs have a lower relative abundance of beneficial taxa that produce anti-inflammatory metabolites such as butyrate. Dr Dalbøge explains that a leaky gut due to low butyrate production may lead to increased inflammation, potentially exacerbating MPN symptoms, although the exact relationship between MPN and the gut microbiota remains unclear. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
